Perkin G D, Aminoff M J
Br J Clin Pharmacol. 1976 Oct;3(5):879-82. doi: 10.1111/j.1365-2125.1976.tb00641.x.
A new anti-spasticity agent, brolitene, has been assessed in patients with spasticity of spinal or cerebral origin. Twenty-seven patients were entered in a double-blind cross-over trial lasting 6 weeks, using a fixed dose of six tablets (1200 mg brolitene) per day. Clinical assessment failed to show any therapeutic effect in the seventeen patients completing the trial, except in one with multiple sclerosis. Ten patients had to be withdrawn from the trial, six while being treated with the active agent.
一种新型抗痉挛药物溴利烯已在患有脊髓性或脑源性痉挛的患者中进行了评估。27名患者进入了一项为期6周的双盲交叉试验,每天固定服用6片(1200毫克溴利烯)。临床评估显示,在完成试验的17名患者中,除一名患有多发性硬化症的患者外,未发现任何治疗效果。10名患者不得不退出试验,其中6名是在接受活性剂治疗时退出的。